• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    11/24/23 8:06:43 AM ET
    $AEMD
    $ASMB
    $BPTS
    $FEMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEMD alert in real time by email

    Gainers

    • Telesis Bio (NASDAQ:TBIO) shares moved upwards by 32.5% to $0.53 during Friday's pre-market session. The company's market cap stands at $15.8 million.
    • Femasys (NASDAQ:FEMY) shares increased by 14.9% to $1.05. The company's market cap stands at $22.7 million.
    • Medigus (NASDAQ:MDGS) stock rose 10.99% to $3.13. The company's market cap stands at $5.3 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock rose 10.0% to $0.55. The company's market cap stands at $5.1 million.
    • Assembly Biosciences (NASDAQ:ASMB) stock moved upwards by 9.99% to $0.71. The company's market cap stands at $46.7 million.
    • PaxMedica (NASDAQ:PXMD) shares moved upwards by 9.8% to $1.12. The market value of their outstanding shares is at $1.2 million.

    Losers

    • vTv Therapeutics (NASDAQ:VTVT) shares declined by 96.8% to $0.35 during Friday's pre-market session.
    • Impel Pharmaceuticals (NASDAQ:IMPL) stock declined by 31.96% to $0.53. The company's market cap stands at $12.6 million.
    • Aethlon Medical (NASDAQ:AEMD) shares decreased by 17.16% to $1.4. The company's market cap stands at $3.4 million.
    • Ikena Oncology (NASDAQ:IKNA) shares declined by 12.27% to $1.43. The company's market cap stands at $69.0 million.
    • Biophytis (NASDAQ:BPTS) shares fell 10.74% to $0.7. The market value of their outstanding shares is at $6.8 million.
    • Heart Test Laboratories (NASDAQ:HSCS) stock decreased by 10.56% to $0.21. The market value of their outstanding shares is at $10.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $ASMB
    $BPTS
    $FEMY

    CompanyDatePrice TargetRatingAnalyst
    vTv Therapeutics Inc.
    $VTVT
    1/23/2026$58.00Buy
    Roth Capital
    vTv Therapeutics Inc.
    $VTVT
    1/5/2026$67.00Buy
    TD Cowen
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    vTv Therapeutics Inc.
    $VTVT
    11/19/2025$40.00Buy
    BTIG Research
    Assembly Biosciences Inc.
    $ASMB
    9/24/2025$38.00Mkt Outperform
    Citizens JMP
    Assembly Biosciences Inc.
    $ASMB
    8/18/2025$50.00Buy
    H.C. Wainwright
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    Assembly Biosciences Inc.
    $ASMB
    3/25/2025$31.00Buy
    Guggenheim
    More analyst ratings

    $AEMD
    $ASMB
    $BPTS
    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted to two new non-executive employees who began their employment with Femasys in February 2026 options to purchase 185,000 shares of Femasys common stock. These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the closing price of Femasys common stock on the date of employment as reported by Nasdaq. This grant was approved by the Compensation Committee of Femasys' Board of Directors and made as an inducement

    2/27/26 5:26:33 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access

    -- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that its FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program (MDSAP). The MDSAP certification positions the Company to accelerate regulatory and commercial execution across key global markets, including the United States, Canada, Japan, Australia, and Brazil. In the U.S., FDA

    2/26/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Presenting on Emerging Growth Conference 90 Day 2 on February 26; Register to live stream

    MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - February 25, 2026 – Agenda for Today: 8:45Virtual Lobby opens.Register for the Conference. If you already regi

    2/25/26 7:00:00 AM ET
    $AEMD
    $ASPI
    $CLNN
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

    $AEMD
    $ASMB
    $BPTS
    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Lee-Sepsick Kathy

    4 - FEMASYS INC (0001339005) (Issuer)

    2/20/26 5:37:51 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Elefant Dov

    4 - FEMASYS INC (0001339005) (Issuer)

    2/20/26 5:32:25 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by EVP & CFO Tung Michael Stephen

    4 - vTv Therapeutics Inc. (0001641489) (Issuer)

    2/18/26 4:11:09 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASMB
    $BPTS
    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on vTv Therapeutics with a new price target

    Roth Capital initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $58.00

    1/23/26 8:21:38 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on vTv Therapeutics with a new price target

    TD Cowen initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $67.00

    1/5/26 8:58:53 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw initiated coverage on Femasys with a new price target

    Laidlaw initiated coverage of Femasys with a rating of Buy and set a new price target of $6.50

    11/20/25 8:06:38 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ASMB
    $BPTS
    $FEMY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $AEMD
    $ASMB
    $BPTS
    $FEMY
    SEC Filings

    View All

    $AEMD
    $ASMB
    $BPTS
    $FEMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - vTv Therapeutics Inc. (0001641489) (Filer)

    2/26/26 7:51:23 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aethlon Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    2/23/26 4:15:32 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Aethlon Medical Inc.

    10-Q - AETHLON MEDICAL INC (0000882291) (Filer)

    2/12/26 5:10:41 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Large owner Gilead Sciences, Inc. bought 2,295,920 shares, increasing direct ownership by 104% to 4,505,391 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    10/3/25 4:30:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:51:45 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:47:09 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $ASMB
    $BPTS
    $FEMY
    Leadership Updates

    Live Leadership Updates

    View All

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

    HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internationally recognized leaders in endocrinology, diabetes research, clinical trial design, and regulatory science, will continue providing strategic guidance on the development of cadisegliatin, which is currently being investigated in Phase 3 clinical trials as an oral adjunctive therapy to insulin for the treatment of type 1

    10/9/25 8:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

    --Existing investors, including Femasys' largest shareholders, reaffirm confidence in Femasys' strategy for growth and impact in women's health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today the closing of $8 million in financing. This funding will provide critical resources to accelerate commercialization efforts and strengthen the company's ability to address significant unmet needs in women's reproductive health. To underscore this momentum, Femasys' largest shareholder, Jorey Chernett also provided co

    9/2/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ASMB
    $BPTS
    $FEMY
    Financials

    Live finance-specific insights

    View All

    $AEMD
    $ASMB
    $BPTS
    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

    SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034

    2/4/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

    – 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study – – 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 – – Company to hold conference call today at 6 p.m. ET – SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting seri

    12/8/25 4:05:00 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Ikena Oncology Inc.

    SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)

    11/14/24 5:05:17 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care